

# AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph beginning on page 2, line 26, as follows.

Preferably, the heterologous protein of the present invention is selected from the group consisting of those proteins that are known to be active only when expressed in mammalian cells (such as EPO, TPA, Factor VIII, etc.) and preferably, the vector contains a promoter selected from the group consisting of SV early promoter, major immediate early promoter of human cytomegalovirus (hereafter "HCMV MIEP") and RSV LTR, and preferably, the avian cell is selected from the group consisting of duck embryo cell (hereafter "DE"), chicken embryo fibroblast (hereafter "CEF") and quail fibrosarcoma (hereafter "QT"), more preferably QT-VC which was isolated by the inventors. ~~QT-VCN4D4~~ was deposited to the International Depository Authority, Korea Research Institute of Bioscience and Biotechnology Korean Collection for Type Culture as identification reference of QT35-N4D4, and assigned a deposit number of KCTC 0277BP on August 22, 1996. The ~~deposited~~ QT-VC was transfected with the expression vector containing SY-EPO cDNA to obtain a QT-N4D4 which is stably expressing EPO as described in Fig. 8.

Please amend Table 1 on page 8 as follows.

Cells	Source
HeLa human cervical carcinoma cells	ATCC CCL2
Vero African green monkey kidney cells	ATCC CCL81
COS-7 African green monkey kidney cells transformed by wild-type T antigen of SV40	ATCC CRL1651
CHO-K1 Chinese hamster ovary cells	ATCC CCL61
NIH3T3 contacted-inhibited Swiss mouse embryo cells	ATCC CRL1651
Ad-5 transformed human embryonic kidney cells 293	ATCC CRL1651
SL-29 chicken embryo fibroblast cells	ATCC CRL1590
Duck embryo	ATCC CCL141 or prepared by the inventors
Quail fibrosarcoma line QT6	ATCC CRL1708
Quail fibrosarcoma line QT-VC	Isolated by the inventors KCTC 0277BP